Related Experiment Videos
Miconazole mucoadhesive tablets: a novel delivery system
1Department of Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI 48201, USA. jvazque1@hfhs.org
Summary
A new once-daily miconazole buccal tablet effectively treats oropharyngeal candidiasis (OPC) in HIV patients. This convenient topical option shows potent activity, even against azole-resistant Candida species.
Area of Science:
- Infectious Diseases
- Pharmacology
- HIV/AIDS Research
Background:
- Oropharyngeal candidiasis (OPC) is a frequent opportunistic infection in individuals with human immunodeficiency virus (HIV).
- Emerging azole resistance in Candida species necessitates novel therapeutic strategies.
- Topical antifungal treatments are crucial for managing oral fungal infections in immunocompromised populations.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) for treating OPC.
- To assess the convenience and tolerability of the MBT formulation.
- To investigate the in vitro activity of MBT against various Candida species, including azole-resistant strains.
Main Methods:
- A novel mucoadhesive buccal tablet (MBT) formulation delivering miconazole 50 mg once daily was utilized.
- In vitro susceptibility testing was performed against a panel of Candida species.
- Clinical efficacy and safety data were collected for patients with OPC.
Main Results:
- The miconazole mucoadhesive buccal tablet (MBT) demonstrated potent in vitro activity against numerous Candida species.
- MBT showed efficacy against some Candida strains exhibiting resistance to other azole antifungals.
- The once-daily MBT was found to be an effective, safe, and well-tolerated topical treatment for OPC.
Conclusions:
- The once-daily miconazole mucoadhesive buccal tablet (MBT) represents a valuable new therapeutic option for oropharyngeal candidiasis (OPC).
- MBT offers a convenient and effective treatment, particularly for patients with HIV and potentially azole-resistant fungal infections.
- This novel delivery system provides a safe and well-tolerated alternative for managing OPC.
Related Concept Videos
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:23Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...